Joint Formulary & PAD

Selegiline hydrochloride - Parkinson's disease

You are here : Home > Formulary Search > Selegiline hydrochloride - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :

Documentation

Guidelines (National)
NICE NG71 Parkinsons-disease-in-adults

PAD Profile

ChemicalSubstance :
Selegiline hydrochloride
Indication :
Parkinson's disease
Group Name :
Keywords :
Parkinsons disease, PD, monoamine-oxidase-B inhibitors, MAOB
Brand Names Include :
Eldepryl, Zelapar
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

06 Jun 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
  •  Monoamine-oxidase-B inhibitors (rasagiline, selegiline), (or levodopa or dopamine agonists) are a first-line treatment option in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
  • Monoamine-oxidase-B inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.

Patients in whom Parkinson's is suspected should be referred quickly and untreated to a specialist.

Initiation may be carried out in Primary Care but only after recommendation by a specialist.
Modifications to therapy should only be carried out on specilaist advice.

Prescribers are reminded to prescribe generically and not by brand.

 

Other Indications

Below are listed other indications that Selegiline hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Parkinson's disease.